 | Up a level |
van der Kolk, J H; Thomas, S; Mach, N; Ramseyer, A.; Burger, D; Gerber, Vinzenz; Nuoffer, J.-M. (2020). Serum acylcarnitine profile in endurance horses with and without metabolic dysfunction. The veterinary journal, 255, p. 105419. Elsevier 10.1016/j.tvjl.2019.105419
Joerger, M; Metaxas, Y; Schmitt, AM; Koeberle, D; Zaman, K; Betticher, D; Mach, N; Renner, C; Mark, M; Petrausch, U; Caspar, C; Britschgi, C; Taverna, C; Zenger, F; Mingrone, W; Schulz, J; Kopp, C; Hayoz, S; Stathis, A and von Moos, R (2020). Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA) (Unpublished). In: Virtual ESMO 2020.
Gautschi, O; Li, Q; Matter-Walstra, K; Betticher, D; Frueh, M; Rauch, Daniel; Pless, M; Froesch, P; Mach, N; Ochsenbein, Adrian (2016). 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial. Journal of thoracic oncology, 11(4Suppl), S120-S120. Elsevier 10.1016/S1556-0864(16)30253-2
D'Addario, G; Rauch, D; Stupp, R; Pless, M; Stahel, R; Mach, N; Jost, L; Widmer, L; Tapia, C; Bihl, M; Mayer, M; Ribi, K; Lerch, S; Bubendorf, L; Betticher, D C (2007). Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. Annals of oncology, 19(4), pp. 739-745. Oxford: Oxford University Press 10.1093/annonc/mdm564
